News | February 14, 2025
IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Cipla has reported consolidated financial results for the period ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
